BioPharma Resources

Drug Trial Radar · NCT05397678

Trial to Compare BCG-Bulgaria and BCG-Denmark

Randomized Trial Evaluating the Non-specific Effects of BCG-Bulgaria and BCG-Denmark in Guinea-Bissau: Effects on Mortality, Morbidity, and BCG Skin Reactions

Last checked: Nov 19, 2026Latest source record: Jan 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 15,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

15,000

Planned (sponsor's estimate)

Start

Oct 21, 2022

Primary completion

Jul 2024

Study completion Oct 2024

Sponsor

Lead sponsor
Bandim Health ProjectAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Southern Denmark
First posted
May 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (care provider, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 0 days, up to 1 year
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The trial will be a two-year outcome assessor-blinded RCT at the maternity ward of Hospital Simão Mendes (HNSM) in urban Bissau, Guinea-Bissau to compare vaccination with Bacillus Calmette-Guérin (BCG) Danish strain (AJ Vaccines, Copenhagen 1331 strain) versus BCG-Bulgaria (BB-NCIPD, BCG-SL 222 Sofia strain) 1:1 in 15,000 infants with respect to mortality, morbidity and case-fatality rate during hospital admission. The trial will also examine the association between BCG strains and BCG skin reaction kinetics and characteristics. As a secondary aim, this large study will be used to further evaluate the role of maternal BCG immune priming for overall health, since there are indications that the maternal BCG scar status influences offspring health outcomes.

Conditions

  • Death; Neonatal
  • Death, Infant
  • Morbidity;Newborn
  • Morbidity;Infant
  • Non-specific Effects of Vaccines

Interventions

  • BCG-DenmarkBiological

    AJ vaccines, Copenhagen 1331 strain

  • BCG-BulgariaBiological

    BB-NCIPD Ltd., BCG-SL 222 Sofia strain

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause mortality riskTime frame: Six weeks of age

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bandim Health Project

    Bissau, Guinea-Bissau · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.